ClinicalTrials.gg
Active, not recruitingNCT06645886Updated Mar 25, 2026

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

A Phase 1 interventional study of KQB198 and Dasatinib in Hematologic Malignancies and Adult, sponsored by Kumquat Biosciences Inc.. Active, not recruiting at 29 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Kumquat Biosciences Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
526th of 658
13 · median 40
Started
2024
with 30 others
Phase 1
195 of 821
35 open now
Primary completion
2027-03
later than 116 of 273 live
Registered
752nd of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 526th largest by enrollment of the 658 interventional ones that give a count, is one of 31 that started in 2024, is one of 195 in phase 1, reaches primary completion later than 116 of the 273 other live ones, and was the 752nd registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:

  • What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
  • Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
  • What happens to KQB198 in the body?

Participants will:

  • Take KQB198 daily, alone or in combination with another anti-cancer drug
  • Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that
03

Conditions studied

  • Hematologic Malignancies
  • Adult

Keywords

  • CML
  • dasatinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequate organ function

Part 1 and Part 2, Cohort B Participants Only:

  • Ph+ CML in chronic phase who have been previously treated with at least 2 different tyrosine kinase inhibitors (TKIs) and are from or intolerant to those TKIs and ineligible for alternative therapeutic options likely to produce clinical benefit as determined by the investigator.

Part 2, Cohort A Participants Only:

  • Participants with Ph+ CML in chronic phase who are on dasatinib prior to study entry and have a warning or failure to dasatinib as determined by the investigator per ELN 2020 guidelines

Exclusion criteria

Exclusion Criteria:

  • CML in accelerated or blast phase
  • Prior therapy with a similar mechanism of action to KQB198
  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • History of interstitial lung disease
  • Cardiac abnormalities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Monotherapy Dose Escalation

    Drug: KQB198

  • Experimental
    Combo Therapy Dose Escalation

    Drug: KQB198 · Drug: Dasatinib

  • Experimental
    Combo Therapy Dose Expansion - RP2D

    Drug: KQB198 · Drug: Dasatinib

  • Experimental
    Combo Therapy Dose Expansion - RP2D-1

    Drug: KQB198 · Drug: Dasatinib

  • Experimental
    Monotherapy Dose Expansion - RP2D

    Drug: KQB198

  • Experimental
    Monotherapy Dose Expansion - RP2D -1

    Drug: KQB198

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 28 days after last dose of study treatment.

    Time frame: 28 Days

  2. Recommended Phase 2 Dose (RP2D) (Part 1)

    Evaluate safety and assess number of patients with dose-limiting toxicity to determine the RP2D.

    Time frame: Up to 30 months

  3. Efficacy of study treatment and optimal biologic dose, as measured by molecular response (MR) per European Leukemia Network (ELN) 2020 Guidelines (Part 2).

    Molecular response is the percentage of BCR-ABL fusion protein found in blood. Calculation of molecular response in Part 2 Cohort A will be the proportion of subjects that experience molecular response 4 (MR4) during the time period from 1st dose of study treatment until 6 months of study treatment. Calculation of molecular response in part 2 cohort B will be the proportion of subjects that experience molecular response 3 (MR3) during the time period from 1st dose of study treatment until 6 months of study treatment.

    Time frame: Up to 6 Months

Secondary outcomes

  1. Efficacy of Study Treatment

    Efficacy of study treatment as measured by molecular response (MR) at 3, 6, 9, and 12 months, and anytime.

    Time frame: Up to 30 months

  2. Efficacy of Study Treatment

    Efficacy of study treatment as measured by duration of response (DOR). DOR is defined as the time from the date when the response is first observed till the date the response is lost or death, whichever is earlier.

    Time frame: Up to 30 Months

  3. Efficacy of Study Treatment

    Efficacy of study treatment as measured by time to response (TTR). Response assessments will be summarized by all reported response categories at each visit.

    Time frame: Up to 30 months

  4. Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 2)

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs from first dose of study treatment to 28 days after last dose of study treatment.

    Time frame: 28 Days After Last Dose

  5. Concentration-Time Curve (AUC)

    Time frame: Up to 30 months

  6. Maximum Plasma Concentration (Cmax)

    Time frame: Up to 30 months

  7. Time to Maximum Plasma Concentration (tmax)

    Time frame: Up to 30 months

07

Study locations

29 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 27 months is below that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 17, 2024
StartActual
Dec 9, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06645886
Lead sponsor
Kumquat Biosciences Inc.
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Dec 9, 2024
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SOS1 Inhibitor MRTX0902

Start the discussion